b'Thoughmanyrecentlyapprovedmedications attentionforitspotentialroleasanadjunctaredeliveredbyinjection,therehavebeen therapyforMS.In2010,astudyconductedseveraldevelopmentsforthetreatmentofMS, inIranfoundthatpatientswhoweretreatedthataretabletsorpillstobetakenbymouth. withinterferonmedicationwhoreceivedOzanimodisanoral,once-dailymedication simvastatinadjuncttherapyexperiencedathatwasrecentlygrantedFDAapprovalfor signicantlylowernumberofdiseaseattacks.treatmentofrelapsingMS.PhaseIIIclinical AphaseIIBritishstudythatwasbegunintrialswerepublishedin2019andreected 2008justrecentlypublisheditscompletesignicantlyimprovedecacyoverinterferon resultsandshowedthatpatientstreatedwithbeta-1atherapy,whichistypicallyconsidered simvastatinversusplacebohadsignicantlyrst-lineforrelapsingMS.Resultsofphase betterfrontallobefunctionafteratwo-yearIIIclinicaltrialsshowedthatthismedication trialperiod.slowedtheprogressionofdisability,and Amongthelesssuccessfulmechanismspatientstreatedwiththismedicationhad studiedforthetreatmentofMS,idebenoneisfewerrelapses.Thoughthereareseveralother amedicationthatisasyntheticversionofmedicationsonthemarketthatactinthesame acommondietarysupplement,Coenzymemechanismasozanimod,thisdrugappears Q10.Resultsofathree-yearstudyconductedtohavefewersideeectsandabettersafety bytheNationalInstitutesofHealthwereprole.Themostcommonsideeectswith presentedin2018andshowednosignicantthisdrugincludedsymptomsofthecommon benet.Anothermedication,ibudilast,under-coldandheadaches.Thedruggotreleased wentphaseIIclinicaltrials.ThoughtheunderthebrandnameZeposia. medicationwasfoundtoslowtheprogressionInternational Pipeline ofbrainatrophy,itwasassociatedwithmuchThereareseveralmedicationsthathave higherratesofgastrointestinalsideeects.shownpositivepreliminarytrialresults Conclusioninternationally,andareintheearlystagesof Formanyyears,researchanddevelopmentresearchintheUnitedStates.Forexample, ofmedicationsforMSprogressedslowly,withQizendayisamedicationwhoseactive fewsignicantmilestones.However,inrecentingredientishigh-dosebiotin,orvitamin years,severalnovelmechanismshaveB7.Qizendayhasbeenstudiedinseveral acceleratedprogressandimprovedtreatmentFrenchclinicaltrials,andtherstAmerican forthosediagnosedwithMS.Ofnote,severalstudyiscurrentlyactive,withanestimated oftheearliestapprovedmedicationsforMSstudycompletiondateofJune2023.If arenearingtheendoftheiroriginalpatentecacious,Qizendaycouldbearelatively exclusivity,anditwillbeinterestingtoseeinexpensivetreatmentoptionforpatients howfutureMSguidelinesaredetermined.AswithprogressiveMS. newmedicinesarestudiedandapproved,Simvastatinisamedicationthathasbeen moreresearchisneededcomparingtheseusedforthetreatmentofhighcholesterolfor therapiestodecidewhichwillprovidethemanyyears.Recently,however,ithasgained mostbenet.57 msfocusmagazine.org'